HeartFlow, a provider of non-invasive artificial intelligence (AI) heart care solutions, has unveiled its advanced HeartFlow Plaque Analysis featuring an interactive experience.
According to HeartFlow, this latest innovation from is unique as it fully integrates with fractional flow reserve derived from computed tomography (FFRCT) when such analyses are performed. The integration enhances the utility and insights for clinical decision-making.
The enhanced HeartFlow Plaque Analysis tool utilises proprietary algorithms to scrutinise coronary CT angiogram (CCTA) scans. It generates a personalised 3D model that quantifies and characterises the volume of plaque in the coronary arteries, which is crucial for assessing the risk of coronary artery disease.
HeartFlow debuted the technology at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting held in Washington, D.C.
CV imaging, nuclear and CT medical director Sarah Rinehart from Charleston, West Virginia said: “Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician.
“I can reference the cross-sectional views with plaque by type when reviewing my patient’s workup and have confidence in the accuracy and actionable insights that I know I’ll get from HeartFlow Plaque Analysis.
“With a quantitative measurement of a patient’s plaque volume, I can more accurately assess risk and develop a personalised, targeted treatment plan.”
The upgraded platform enhances its functionality by integrating accurate plaque quantification with lesion-specific FFRCT values. This integration allows for a detailed 3D visualisation of plaque and comprehensive plaque analysis across different territories including calcified, non-calcified, and low attenuation.
Additionally, it provides the ability to view cross-sectional, color-coded images of each plaque type, mapped precisely along the vessel where quantification is done.
HeartFlow chief medical officer Campbell Rogers said: “Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease.
“The elevated visualisation of Plaque Analysis integrated with our flagship FFRCT Analysis, sets HeartFlow apart as a wholistic solution for CT analysis, enabling physicians to enhance personalised treatment decisions.”
